Switch strategies in patients on effective HAART

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 6, 2005, Pages 821-823

  Maggiolo, Franco ^a   Ripamonti, Diego ^a   Suter, Fredy ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

HAART simplification; HIV; NNRTIs; NRTIs; Protease inhibitors; Switch therapy

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LACTIC ACID; LAMIVUDINE; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THYMIDINE DERIVATIVE;

ARTICLE; BODY FAT; BODY WEIGHT DISORDER; CLINICAL PROTOCOL; CLINICAL TRIAL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPOATROPHY; LIPODYSTROPHY; LONG TERM CARE; META ANALYSIS; MONOTHERAPY; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; WEIGHT GAIN;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 21244489655     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki119     Document Type: Article

References (16)

1. Dieleman JP, Sturkenboom MC, Wit FW et al. Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression. J Infect Dis 2002; 185: 1261-8.
2. Maggiolo F, Ripamonti D, Ravasio L et al. Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection. Clin Infect Dis 2003; 37: 41-9.
3. Bucher HC, Kofler A, Nuesch R et al. Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients. AIDS 2003; 17: 2451-9.
4. Clumeck N, Goebel F, Rozenbaum W et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001; 15: 1517-26.
5. Ruiz L, Negredo E, Domingo P et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy. 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr 2001; 27: 229-36.
6. Carr A, Hudson J, Chuah J et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS 2001; 15: 1811-22.
7. Martinez E, Arnaiz JA, Podzamczer D et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349: 1036-46.
8. Estrada V, de Villar N G P, Martinez Larrad MT et al. Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy. Clin Infect Dis 2002; 35: 69-76.
9. Opravil M, Hirschel B, Lazzarin A et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002; 185: 1251-60.
10. Katlama C, Fenske S, Gazzard B et al. TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med 2003; 4: 79-86.
11. Molina JM, Journot V, Morand-Joubert L et al. Simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial. J Infect Dis 2005; 191: 830-9.
12. Stone VE, Jordan J, Tolson J et al. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr 2004; 36: 808-16.
13. Maggiolo F, Ravasio L, Ripamonti D et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 2005; 40: 158-63.
14. Carr A, Workman C, Smith DE et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002; 288: 207-15.
15. McComsey GA, Ward DJ, Hessenthaler SM et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004; 38: 263-70.
16. De Jesus E, Herrera G, Teofilo J et al. Abacavir versus zidovudine combined with lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004; 39: 1038-46.